Friday, May 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Pathogens

Development of SARS-CoV-2 Anti-N Monoclonal Antibodies

by Global Biodefense Staff
September 7, 2020
Development of SARS-CoV-2 Anti-N Monoclonal Antibodies

Novel Coronavirus SARS-CoV-2. Credit: NIAID

The SARS-CoV-2 nucleocapsid protein is a major component of the viral replication processes, integral to viral particle assembly, and is a major diagnostic marker for infection and immune protection.

In a new paper (still under peer review), researchers from Colorado State University describe a newly developed and characterized mouse monoclonal antibodies against the SARS-CoV-2 nucleocapsid protein. The anti-nucleocapsid (anti-N) monoclonal antibodies were tested in ELISA, western blot, and immunofluorescence analyses.The variable regions from the heavy and light chains from five select clones were cloned and sequenced, and preliminary epitope mapping of the sequenced clones was performed.

Future studies can utilize these antibodies for studies determining nucleocapsid protein structure, intracellular interactions, diagnostic development, and potential therapeutics. The new anti-N reagents described here will be of significant value in the fight against COVID-19.

Tags: Editor PickPublic Health EmergencySARS-CoV-2

Related Posts

Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
The device appears smaller than a playing card, transparent, with visible channels branching off.
Medical Countermeasures

How Organ-on-a-chip Models Could Grease the Drug Development Pipeline

January 10, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC